Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

New acne treatments show promise as alternatives to traditional therapies.

This review discusses the role of peroxisome proliferator-activated receptors and their agonists in dermatology but reports no new clinical results.

This review summarizes recent multidisciplinary advances in sebaceous gland research and highlights potential novel therapeutic strategies for skin diseases, but it reports no new clinical results.

This review discusses the chronic nature of acne and its association with various systemic diseases, but reports no new clinical findings, highlighting the need for further study on its nutritional or genetic links.

This article reviews the role of diet in various skin disorders and suggests that dietary changes may aid in managing certain conditions, though it reports no new clinical findings.

This review explores the role of neutrophil recruitment in the inflammation seen in hidradenitis suppurativa and emphasizes potential therapeutic targets within these pathways, but it reports no new clinical results.

This review discusses the pathogenesis of common sebaceous gland diseases and their molecular pathways, but it reports no new clinical findings.

This review discusses current topical treatments, natural products, and complementary therapies for androgenetic alopecia, but it reports no new clinical results.

This article discusses the multifactorial etiopathogenesis of acne vulgaris, highlighting the roles of sebum production, keratosis, bacterial development, and inflammatory mediators, but reports no new clinical results.

This study constructed a panel of pharmacokinetic and pharmacodynamic genes, revealing that current SNP chips insufficiently capture many drug-response gene variants, highlighting the need for complementary genetic approaches.

New acne treatments include combination creams, advanced retinoids, and light therapies, focusing on safety and patient adherence.

This review highlights drug repositioning strategies for discovering new treatments for skin conditions and reports no new clinical results, emphasizing the integration of systematic methods with advances in molecular biology and omics.

This article reviews the multifaceted approach required for acne vulgaris treatment, emphasizing individualized combination therapies tailored to clinical severity and patient psychological profiles, but no new results are included.

This study identified key genes related to ischemic stroke through the ferroptosis pathway and highlighted the potential role of specific traditional Chinese medicines in regulating associated biological processes.

This review revisits the principles regarding the critical role of diet and nutrition in managing certain skin diseases but reports no new findings.

This study found that finasteride significantly inhibits the metabolism of tirilazad to its active metabolites without greatly affecting tirilazad's overall clearance.

This study examined the safety profile of ritlecitinib, a drug for alopecia areata, and found that it does not cause significant QTc prolongation or severe lymphopenia, with no unique safety risks expected in adolescents.

This study found that Litfulo improved hair regrowth in patients aged 12 and older with severe alopecia areata but did not meaningfully improve anxiety or depression symptoms compared to placebo.

The study found that ezetimibe effectively reduced prostate enlargement in an animal model of benign prostatic hyperplasia, suggesting it as a potential alternative or complementary treatment.

In this study, compound zishenqing formula combined with standard medications improved symptoms and immune indices in female SLE patients, with a lower occurrence of side effects compared to standard medications alone.

This study reported that oral simvastatin/ezetimibe therapy was ineffective for treating alopecia areata, with 67% of participants experiencing no hair regrowth. Additionally, 24% of patients experienced adverse effects, including myalgia, highlighting the need to weigh potential risks against questionable benefits.

This article describes the development milestones and recent approvals of ritlecitinib for treating severe alopecia areata, with approvals in the USA and Japan and ongoing regulatory reviews in other regions.

This research reported that the FDA approved Litfulo® (ritlecitinib) as the first oral treatment for severe alopecia areata in adolescents over 12 years old, with 23% of treated patients showing significant hair regrowth in clinical trials compared to 1.6% with placebo.

In this mouse study, researchers found that the Jieduquyuziyin prescription may lessen lupus-like symptoms and atherosclerosis by inhibiting TLR9/MyD88 signaling and promoting cholesterol efflux.

This study found that a combination of low-dose isotretinoin and oral azithromycin pulse effectively treats severe acne with an acceptable side effect profile and relatively low relapse rates.

In this study, simvastatin/ezetimibe treatment led to partial hair regrowth in about 29% of patients with recalcitrant alopecia areata, suggesting it may be a viable alternative therapy for this condition.